Health-care companies ticked down amid mixed fortunes for the sector.
BioCryst Pharmaceuticals shares surged after the biotech firm said it would turn a profit in 2025, a year earlier than anticipated, amid robust demand for Oraldeyo, a treatment for rare disease hereditary angioedema.
BioNTech, the German biotech firm that rose to fame when it partnered with Pfizer on a Covid 19 vaccine, logged a hefty first-quarter loss and said it would focus on promising oncology programs from now on, citing risks to its current franchise from public policy and opinion.
Henry Schein's first-quarter net income rose and the company backed its 2025 adjusted earnings projection as increased doctor-office visits buoyed medical sales, offsetting weakness in demand for dental-supply sales and the impact of a strong dollar.
Health insurer UnitedHealth Group said it now has a thousand artificial-intelligence applications in production.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 05, 2025 17:41 ET (21:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.